Prolyl 4-hydroxylases, master regulators of the hypoxia response

Acta Physiologica

Volumn 208, Issue 2, 2013, Pages 148-165

  Myllyharju, J ^a  

^a UNIVERSITY OF OULU   (Finland)

Author keywords

Hypoxia response; Hypoxia inducible factor; Prolyl 4 hydroxylase

Indexed keywords

2 HYDROXYGLUTARIC ACID; ACTIVATING TRANSCRIPTION FACTOR 4; ARGININE; ERYTHROPOIETIN; FUMARATE HYDRATASE; GULONOLACTONE OXIDASE; HEME OXYGENASE 1; HYPOXIA INDUCIBLE FACTOR; I KAPPA B KINASE BETA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; IRON REGULATORY FACTOR; MESSENGER RNA; PROCOLLAGEN PROLINE 2 OXOGLUTARATE 4 DIOXYGENASE; SHORT HAIRPIN RNA; SUCCINATE DEHYDROGENASE; TRANSCRIPTION FACTOR NRF2; ZINC FINGER PROTEIN;

ADVERSE OUTCOME; ALTERNATIVE RNA SPLICING; AMINO ACID SEQUENCE; ANEMIA; ANGIOGENESIS; BRAIN ISCHEMIA; CAENORHABDITIS ELEGANS; CALORIC RESTRICTION; CARDIOVASCULAR DISEASE; CHLAMYDOMONAS REINHARDTII; CITRIC ACID CYCLE; CRYSTALLIZATION; DROSOPHILA MELANOGASTER; ENZYME ACTIVE SITE; ENZYME INACTIVATION; ENZYME INHIBITION; ERYTHROCYTOSIS; EX VIVO STUDY; HEART LEFT VENTRICLE FAILURE; HEART MUSCLE ISCHEMIA; HUMAN; HYDROXYLATION; HYPOXIA; IN VITRO STUDY; IN VIVO STUDY; INFLAMMATION; MYELOID LEUKEMIA; NEGATIVE FEEDBACK; NONHUMAN; PARAGANGLIOMA; PRIORITY JOURNAL; REPERFUSION INJURY; REVIEW; RNA INTERFERENCE; TRICHOPLAX; ZINC FINGER MOTIF;

ANIMALS; ANOXIA; GENE EXPRESSION REGULATION, ENZYMOLOGIC; OXYGEN; PROCOLLAGEN-PROLINE DIOXYGENASE;

EID: 84877704490     PISSN: 17481708     EISSN: 17481716     Source Type: Journal    
DOI: 10.1111/apha.12096     Document Type: Review

References (217)

1. Acevedo, J.M., Centanin, L., Dekanty, A. & Wappner, P. 2010. Oxygen sensing in Drosophila: multiple isoforms of the prolyl hydroxylase fatiga have different capacity to regulate HIFα/Sima. PLoS ONE 5, e12390.
2. Acker, T., Diez-Juan, A., Aragones, J., Tjwa, M., Brusselmans, K., Moons, L., Fukumura, D., Moreno-Murciano, M.P., Herbert, J.M., Burger, A. et al. 2005. Genetic evidence for a tumor suppressor role of HIF-2α. Cancer Cell 8, 131-141.
3. Adam, J., Hatipoglu, E., O'Flaherty, L., Ternette, N., Sahgal, N., Lockstone, H., Baban, D., Nye, E., Stamp, G.W., Wolhuter, K. et al. 2011. Renal cyst formation in Fh1-deficient mice is independent of the Hif/Phd pathway: roles for fumarate in KEAP1 succination and Nrf2 signaling. Cancer Cell 20, 524-537.
4. Adamcio, B., Sperling, S., Hagemeyer, N., Walkinshaw, G. & Ehrenreich, H. 2010. Hypoxia inducible factor stabilization leads to lasting improvement of hippocampal memory in healthy mice. Behav Brain Res 208, 80-84.
5. -/-) attenuates ex vivo myocardial ischemia/reperfusion injury through hypoxia-inducible factor-1α transcription factor and its target genes in mice. Antioxid Redox Signal 15, 1789-1797.
6. Albiero, E., Ruggeri, M., Fortuna, S., Finotto, S., Bernardi, M., Madeo, D. & Rodeghier, F. 2012. Isolated erythrocytosis: study of 67 patients and identification of three novel germ-line mutations in the prolyl hydroxylase domain protein 2 (PHD2) gene. Haematologica 97, 123-127.
7. Ameln, A.K., Muschter, A., Mamlouk, S., Kalucka, J., Prade, I., Franke, K., Rezaei, M., Poitz, D.M., Breier, G. & Wielockx, B. 2011. Inhibition of HIF prolyl hydroxylase-2 blocks tumor growth in mice through the antiproliferative activity of TGFβ. Cancer Res 71, 3306-3316.
8. Appelhoff, R.J., Tian, Y.M., Raval, R.R., Turley, H., Harris, A.L., Pugh, C.W., Ratcliffe, P.J. & Gleadle, J.M. 2004. Differential function of the prolyl hydroxylases PHD1, PHD2, and PHD3 in the regulation of hypoxia-inducible factor. J Biol Chem 279, 38458-38465.
9. Aragonés, J., Schneider, M., Van Geyte, K., Fraisl, P., Dresselaers, T., Mazzone, M., Dirkz, R., Zacchigna, S., Lemieux, H., Jeoung, N.H. et al. 2008. Deficiency or inhibition of oxygen sensor Phd1 induces hypoxia tolerance by reprogramming basal metabolism. Nat Genet 40, 170-180.
10. Asikainen, T.M., Schneider, B.K., Waleh, N.S., Clyman, R.I., Ho, W.B., Flippin, L.A., Günzler, V. & White, C.W. 2005. Activation of hypoxia-inducible factors in hyperoxia through prolyl 4-hydroxylase blockade in cells and explants of primate lung. Proc Natl Acad Sci USA 102, 10212-10217.
11. Asikainen, T.M., Chang, L.Y., Coalson, J.J., Schneider, B.K., Waleh, N.S., Ikegami, M., Shannon, J.M., Winter, V.T., Grubb, P., Clyman, R.I., Yoder, B.A., Crapo, J.D. & White, C.W. 2006. Improved lung growth and function through hypoxia-inducible factor in primate chronic lung disease of prematurity. FASEB J 20, 1698-1700.
12. Astuti, D., Ricketts, C.J., Chowdhury, R., McDonough, M.A., Gentle, D., Kirby, G., Schlisio, S., Kenchappa, R.S., Carter, B.D., Kaelin, W.G. Jr, Ratcliffe, P.J., Schofield, C.J., Latif, F. & Maher, E.R. 2010. Mutation analysis of HIF prolyl hydroxylases (PHD/EGLN) in individuals with features of phaeochromocytoma and renal cell carcinoma susceptibility. Endocr Relat Cancer 18, 73-83.
13. Bao, W., Qin, P., Needle, S., Erickson-Miller, C.L., Duffy, K.J., Ariazi, J.L., Zhao, S., Olzinski, A.R., Behm, D.J., Pipes, G.C., Jucker, B.M., Hu, E., Lepore, J.J. & Willette, R.N. 2010. Chronic inhibition of hypoxia-inducible factor prolyl 4-hydroxylase improves ventricular performance, remodeling, and vascularity after myocardial infarction in the rat. J Cardiovasc Pharmacol 56, 147-155.
14. Baranova, O., Miranda, L.F., Pichiule, P., Dragatsis, I., Johnson, R.S. & Chavez, J.C. 2007. Neuron-specific inactivation of the hypoxia inducible factor 1α increases brain injury in a mouse model of transient focal cerebral ischemia. J Neurosci 27, 6320-6332.
15. Barrett, T.D., Palomino, H.L., Brondstetter, T.I., Kanelakis, K.C., Wu, X., Haug, P.V., Yan, W., Young, A., Hua, H., Hart, J.C. et al. 2011. Pharmacological characterization of 1-(5-chloro-6-(trifluoromethoxy)-1H-benzoimidazol-2-yl)-1H-pyrazole-4-carboxylic acid (JNJ-42041935), a potent and selective hypoxia-inducible factor prolyl hydroxylase inhibitor. Mol Pharmacol 79, 910-920.
16. Barth, S., Nesper, J., Hasgall, P.A., Wirthner, R., Nytko, K.J., Edlich, F., Katschinski, D.M., Stiehl, D.P., Wenger, R.H. & Camenisch, G. 2007. The peptidyl prolyl cis/trans isomerase FKBP38 determines hypoxia-inducible transcription factor prolyl-4-hydroxylase PHD2 protein stability. Mol Cell Biol 27, 3758-3768.
17. Barth, S., Edlich, F., Berchner-Pfannschmidt, U., Gneuss, S., Jahreis, G., Hasgall, P.A., Fandrey, J., Wenger, R.H. & Camenisch, G. 2009. Hypoxia-inducible factor prolyl-4-hydroxylase PHD2 protein abundance depends on integral membrane anchoring of FKBP38. J Biol Chem 284, 23046-23058.
18. Batti, L., Taylor, C.T. & O'Connor, J.J. 2010. Hydroxylase inhibition reduces synaptic transmission and protects against a glutamate-induced ischemia in the CA1 region of the rat hippocampus. Neuroscience 167, 1014-1024.
19. Berchner-Pfannschmidt, U., Tug, S., Kirsch, M. & Fandrey, J. 2010. Oxygen-sensing under the influence of nitric oxide. Cell Signal 22, 349-356.
20. Bernhardt, W.M., Câmpean, V., Kany, S., Jürgensen, J.-S., Weidemann, A., Warnecke, C., Arend, M., Klaus, S., Günzler, V., Amann, K., Willam, C., Wiesener, M.S. & Eckardt, K.U. 2006. Preconditional activation of hypoxia-inducible factors ameliorates ischemic acute renal failure. J Am Soc Nephrol 17, 1970-1978.
21. Bernhardt, W.M., Gottmann, U., Doyon, F., Buchholz, B., Campean, V., Schödel, J., Reisenbuechler, A., Klaus, S., Arend, M., Flippin, L., Willam, C., Wiesener, M.S., Yard, B., Warnecke, C. & Eckardt, K.U. 2009. Donor treatment with a PHD-inhibitor activating HIFs prevents graft injury and prolongs survival in an allogenic kidney transplant model. Proc Natl Acad Sci USA 106, 21276-21281.
22. Bernhardt, W.M., Wiesener, M.S., Scigalla, P., Chou, J., Schmieder, R.E., Günzler, V. & Eckardt, K.U. 2010. Inhibition of prolyl hydroxylases increases erythropoietin production in ESRD. J Am Soc Nephrol 21, 2151-2156.
23. Berra, E., Benizri, E., Ginouvès, A., Volmat, V., Roux, D. & Pouysségur, J. 2003. HIF prolyl-hydroxylase 2 is the key oxygen sensor setting low steady-state levels of HIF-1α in normoxia. EMBO J 22, 4082-4090.
24. Besarab, A., Frinak, S. & Yee, J. 2009. What is so bad about a hemoglobin level of 12 to 13 g/dL for chronic kidney disease patients anyway? Adv Chronic Kidney Dis 16, 131-142.
25. Bishop, T., Gallagher, D., Pascual, A., Lygate, C.A., de Bono, J.P., Nicholls, L.G., Ortega-Saenz, P., Oster, H., Wijeyekoon, B., Sutherland, A.I. et al. 2008. Abnormal sympathoadrenal development and systemic hypotension in PHD3-/- mice. Mol Cell Biol 28, 3386-3400.
26. Bordoli, M.R., Stiehl, D.P., Borsig, L., Kristiansen, G., Hausladen, S., Schraml, P., Wenger, R.H. & Camenisch, G. 2011. Prolyl-4-hydroxylase PHD2- and hypoxia-inducible factor 2-dependent regulation of amphiregulin contributes to breast tumorigenesis. Oncogene 30, 548-560.
27. Bruick, R.K. & McKnight, S.L. 2001. A conserved family of prolyl 4-hydroxylases that modify HIF. Science 294, 1337-1340.
28. Bunn, H.F. 2007. New agents that stimulate erythropoiesis. Blood 109, 868-873.
29. Cai, Z., Zhong, H., Bosch-Marce, M., Fox-Talbot, K., Wang, L., Wei, C., Trush, M.A. & Semenza, G.L. 2008. Complete loss of ischaemic preconditioning-induced cardioprotection in mice with partial deficiency of HIF-1α. Cardiovasc Res 77, 463-470.
30. Centanin, L., Ratcliffe, P.J. & Wappner, P. 2005. Reversion of lethality and growth defects in Fatiga oxygen-sensor mutant flies by loss of hypoxia-inducible factor-α/Sima. EMBO Rep 6, 1070-1075.
31. Cervera, A.M., Apostolova, N., Luna-Crespo, F., Sanjuan-Pla, A., Garcia-Bou, R. & McCreath, K.J. 2006. An alternatively spliced transcript of the PHD3 gene retains prolyl hydroxylase activity. Cancer Lett 233, 131-138.
32. Chan, D.A., Suthpin, P.D., Yen, S.-E. & Giaccia, A.J. 2005. Coordinate regulation of the oxygen-dependent degradation domains of hypoxia-inducible factor 1α. Mol Cell Biol 25, 6415-6426.
33. Chan, D.A., Kawahara, T.L., Sutphin, P.D., Chang, H.Y., Chi, J.T. & Giaccia, A.J. 2009. Tumor vasculature is regulated by PHD2-mediated angiogenesis and bone marrow-derived cell recruitment. Cancer Cell 15, 527-538.
34. Chen, R.L., Nagel, S., Papadakis, M., Bishop, T., Pollard, P., Ratcliffe, P.J., Pugh, C.W. & Buchan, A.M. 2012. Roles of individual prolyl-4-hydroxylase isoforms in the first 24 hours following transient focal cerebral ischaemia: insights from genetically modified mice. J Physiol 590, 4079-4091.
35. Choi, K. O., Lee, T., Lee, N., Kim, J. H., Yang, E. G., Yoon, J. M., Kim, J. H., Lee, T. G. & Park, H. 2005. Inhibition of the catalytic activity of hypoxia-inducible factor-1alpha-prolyl-hydroxylase 2 by a MYND-type zinc finger. Mol Pharmacol 68, 1803-1809.
36. Chowdhury, R., McDonough, M.A., Mecinović, J., Loenarz, C., Flashman, E., Hewitson, K.S., Domene, C. & Schofield, C.J. 2009. Structural basis for binding of hypoxia-inducible factor to the oxygen-sensing prolyl hydroxylases. Structure 17, 981-989.
37. Chowdury, R., Hardy, A. & Schofield, C.J. 2008. The human oxygen sensing machinery and its manipulation. Chem Soc Rev 37, 1308-1319.
38. Cramer, T., Yamanishi, Y., Clausen, B.E., Förster, I., Pawlinski, R., Mackman, N., Haase, V.H., Jaenisch, R., Corr, M., Nizet, V., Firestein, G.S., Gerber, H.P., Ferrara, N. & Johnson, R.S. 2003. HIF-1α is essential for myeloid cell-mediated inflammation. Cell 112, 645-657.
39. Cummins, E.P., Berra, E., Comerford, K.M., Ginouves, A., Fitzgerald, K.T., Seeballuck, F., Godson, C., Nielsen, J.E., Moynagh, P., Pouyssegur, J. & Taylor, C.T. 2006. Prolyl hydroxylase-1 negatively regulates IκB kinase-β, giving insight into hypoxia-induced NFκB activity. Proc Natl Acad Sci USA 28, 18154-18159.
40. Cummins, E.P., Seeballuck, F., Keely, S.J., Mangan, N.E., Callanan, J.J., Fallon, P.G. & Taylor, C.T. 2008. The hydroxylase inhibitor dimethyloxalylglycine is protective in a murine model of colitis. Gastroenterology 134, 156-165.
41. Dang, L., White, D.W., Gross, S., Bennett, B.D., Bittinger, M.A., Driggers, E.M., Fantin, V.R., Jang, H.G., Jin, S., Keenan, M.C. et al. 2009. Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature 465, 966.
42. D'Angelo, G., Duplan, E., Boyer, N., Vigne, P. & Frelin, C. 2003. Hypoxia up-regulates prolyl hydroxylase activity. A feedback mechanism that limits HIF-1 responses during reoxygenation. J Biol Chem 278, 38183-38187.
43. Dicato, M. & Plawny, L. 2010. Erythropoietin in cancer patients: pros and cons. Curr Opin Oncol 22, 307-311.
44. Duan, L.J., Takeda, K. & Fong, G.H. 2011. Prolyl hydroxylase domain protein 2 (PHD2) mediates oxygen-induced retinopathy in neonatal mice. Am J Pathol 178, 1881-1890.
45. Eckle, T., Köhler, D., Lehmann, R., El Kasmi, K. & Eltzschig, H.K. 2008. Hypoxia-inducible factor-1 is central to cardioprotection: a new paradigm for ischemic preconditioning. Circulation 118, 166-175.
46. Eckle, T., Hartmann, K., Bonney, S., Reithel, S., Mittelbronn, M., Walker, L.A., Lowes, B.D., Han, J., Borchers, C.H., Buttrick, P.M., Kominsky, D.J., Colgan, S.P. & Eltzschig, H.K. 2012. Adora2b-elicited Per2 stabilization promotes a HIF-dependent metabolic switch crucial for myocardial adaptation to ischemia. Nat Med 18, 774-782.
47. Ehrismann, D., Flashman, E., Genn, D.N., Mathioudakis, N., Hewitson, K.S., Ratcliffe, P.J. & Schofield, C.J. 2007. Studies on the activity of the hypoxia-inducible-factor hydroxylases using an oxygen consumption assay. Biochem J 401, 227-234.
48. Eltzschig, H.K. & Carmeliet, P. 2011. Hypoxia and inflammation. N Engl J Med 364, 656-665.
49. Epstein, A.C., Gleadle, J.M., McNeill, L.A., Hewitson, K.S., O'Rourke, J., Mole, D.R., Mukherji, M., Metzen, E., Wilson, M.I., Dhanda, A. et al. 2001. C. elegans EGL-9 and mammalian homologs define a family of dioxygenases that regulate HIF by prolyl hydroxylation. Cell 107, 43-54.
50. Flashman, E., Bagg, E.A.L., Chowdhury, R., Mecinovic, J., Loenarz, C., McDonough, M.A., Hewitson, K.S. & Schofield, C.J. 2008. Kinetic rationale for selectivity towards N- and C-terminal oxygen dependent degradation domain substrates mediated by a loop region of HIF prolyl hydroxylases. J Biol Chem 283, 3808-3815.
51. Flashman, E., Davies, S.L., Yeoh, K.K. & Schofield, C.J. 2010a. Investigating the dependence of the hypoxia-inducible factor hydroxylases (factor inhibiting HIF and prolyl hydroxylase domain 2) on ascorbate and other reducing agents. Biochem J 427, 135-142.
52. Flashman, E., Hoffart, L.M., Hamed, R.B., Bollinger, J.M. Jr, Krebs, C. & Schofield, C.J. 2010b. Evidence for the slow reaction of hypoxia-inducible factor prolyl hydroxylase 2 with oxygen. FEBS J 277, 4089-4099.
53. Fraisl, P., Aragonés, J. & Carmeliet, P. 2009. Inhibition of oxygen sensors as a therapeutic strategy for ischaemic and inflammatory disease. Nat Rev Drug Discov 8, 139-152.
54. Greer, S.N., Metcalf, J.L., Wang, Y. & Ohh, M. 2012. The updated biology of hypoxia-inducible factor. EMBO J 31, 2448-2460.
55. Grenz, A., Clambey, E. & Eltzschig, H.K. 2012. Hypoxia signaling during intestinal ischemia and inflammation. Curr Opin Crit Care 18, 178-185.
56. Haase, V.H. 2010. Hypoxic regulation of erythropoiesis and iron metabolism. Am J Physiol Renal Physiol 299, F1-F13.
57. Hanson, E.S., Rawlins, M.L. & Leibold, E.A. 2003. Oxygen and iron regulation of iron regulatory protein 2. J Biol Chem 278, 40337-40342.
58. Harten, S.K., Ashcroft, M. & Maxwell, P.H. 2010. Prolyl hydroxylase domain inhibitors: a route to HIF activation and neuroprotection. Antioxid Redox Signal 12, 459-480.
59. Heikkilä, M., Pasanen, A., Kivirikko, K.I. & Myllyharju, J. 2011. Roles of the human hypoxia-inducible factor (HIF)-3α variants in the hypoxia response. Cell Mol Life Sci 68, 3885-3901.
60. Heindryckx, F., Kuchnio, A., Casteleyn, C., Coulon, S., Olievier, K., Colle, I., Geerts, A., Libbrecht, L., Carmeliet, P. & Van Vlierberghe, H. 2012. Effect of prolyl hydroxylase domain-2 haplodeficiency on the hepatocarcinogenesis in mice. J Hepatol 57, 61-68.
61. Henze, A.T. & Acker, T. 2010. Feedback regulators of hypoxia-inducible factors and their role in cancer biology. Cell Cycle 9, 2749-2763.
62. Hewitson, K.S., McNeill, L.A., Riordan, M.V., Tian, Y.M., Bullock, A.N., Welford, R.W., Elkins, J.M., Oldham, N.J., Bhattacharya, S., Gleadle, J.M., Ratcliffe, P.J., Pugh, C.W. & Schofield, C.J. 2002. Hypoxia-inducible factor (HIF) asparagine hydroxylase is identical to factor inhibiting HIF (FIH) and is related to the cupin structural family. J Biol Chem 277, 26351-26355.
63. Hewitson, K.S., Liénard, B.M., McDonough, M.A., Clifton, I.J., Butler, D., Soares, A.S., Oldham, N.J., McNeill, L.A. & Schofield, C.J. 2007. Structural and mechanistic studies on the inhibition of the hypoxia-inducible transcription factor hydroxylases by tricarboxylic acid cycle intermediates. J Biol Chem 282, 3293-3301.
64. Hill, P., Shukla, D., Tran, M.G.B., Aragones, J., Cook, H.T., Carmeliet, P. & Maxwell, P.H. 2008. Inhibition of hypoxia inducible factor hydroxylases protects against renal ischemia-reperfusion injury. J Am Soc Nephrol 19, 39-46.
65. Hindryckx, P., De Vos, M., Jacques, P., Ferdinande, L., Peeters, H., Olievier, K., Bogaert, S., Brinkman, B., Vandenabeele, P., Elewaut, D. & Laukens, D.J. 2010. Hydroxylase inhibition abrogates TNF-α-induced intestinal epithelial damage by hypoxia-inducible factor-1-dependent repression of FADD. Immunol 185, 6306-6316.
66. Hirsilä, M., Koivunen, P., Günzler, V., Kivirikko, K.I. & Myllyharju, J. 2003. Characterization of the human prolyl 4-hydroxylases that modify the hypoxia-inducible factor. J Biol Chem 278, 30772-30780.
67. Hirsilä, M., Koivunen, P., Xu, L., Seeley, T., Kivirikko, K.I. & Myllyharju, J. 2005. Effect of desferrioxamine and metals on the hydroxylases in the oxygen sensing pathway. FASEB J 19, 1308-1310.
68. Hölscher, M., Silter, M., Krull, S., von Ahlen, M., Hesse, A., Schwartz, P., Wielockx, B., Breier, G., Katschinski, D.M. & Zieseniss, A. 2011. Cardiomyocyte-specific prolyl-4-hydroxylase domain 2 knock out protects from acute myocardial ischemic injury. J Biol Chem 286, 11185-11194.
69. Hon, W.C., Wilson, M.I., Harlos, K., Claridge, T.D., Schofield, C.J., Pugh, C.W., Maxwell, P.H., Ratcliffe, P.J., Stuart, D.I. & Jones, E.Y. 2002. Structural basis for the recognition of hydroxyproline in HIF-1α by pVHL. Nature 417, 975-978.
70. Hsieh, M.M., Linde, N.S., Wynter, A., Metzger, M., Wong, C., Langsetmo, I., Lin, A., Smith, R., Rodgers, G.P., Donahue, R.E., Klaus, S.J. & Tisdale, J.F. 2007. FG-2216 HIF prolyl hydroxylase inhibition results in endogenous erythropoietin induction, erythrocytosis, and modest fetal hemoglobin expression in rhesus macaques. Blood 110, 2140-2147.
71. Huang, M., Chan, D.A., Jia, F., Xie, X., Li, Z., Hoyt, G., Robbins, R.C., Chen, X., Giaccia, A.J. & Wu, J.C. 2008. Short hairpin RNA interference therapy for ischemic heart disease. Circulation 118, S226-S233.
72. Huang, H., Van de Veire, S., Dalal, M., Parlier, R., Semba, R.D., Carmeliet, P. & Vinores, S.A. 2011. Reduced retinal neovascularization, vascular permeability, and apoptosis in ischemic retinopathy in the absence of prolyl hydroxylase-1 due to the prevention of hyperoxia-induced vascular obliteration. Invest Ophthalmol Vis Sci 52, 7565-7573.
73. Hyvärinen, J., Hassinen, I.E., Sormunen, R., Mäki, J.M., Kivirikko, K.I., Koivunen, P. & Myllyharju, J. 2010a. Hearts of hypoxia-inducible factor prolyl 4-hydroxylase-2 hypomorphic mice show protection against acute ischemia-reperfusion injury. J Biol Chem 285, 13646-13657.
74. Hyvärinen, J., Parikka, M., Sormunen, R., Rämet, M., Tryggvason, K., Kivirikko, K.I., Myllyharju, J. & Koivunen, P. 2010b. Deficiency of a transmembrane prolyl 4-hydroxylase in the zebrafish leads to basement membrane defects and compromised kidney function. J Biol Chem 285, 42023-42032.
75. Illingworth, C.J.R., Loenarz, C., Schofield, C.J. & Domene, C. 2010. Chemical basis for the selectivity of the von Hippel Lindau tumor suppressor pVHL for prolyl-hydroxylated HIF-1α. Biochemistry 49, 6936-6944.
76. Isaacs, J.S., Jung, Y.J., Mole, D.R., Lee, S., Torres-Cabala, C., Chung, Y.-L., Merino, M., Trepel, J., Zbar, B., Toro, J., Ratcliffe, P.J., Linehan, W.M. & Neckers, L. 2005. HIF overexpression correlates with biallelic loss of fumarate hydratase in renal cancer: novel role of fumarate in regulation of HIF stability. Cancer Cell 8, 143-153.
77. 2 sensing. Science 292, 464-468.
78. Ivan, M., Haberberger, T., Gervasi, D.C., Michelson, K.S., Günzler, V., Kondo, K., Yang, H., Sorokina, I., Conaway, R.C., Conaway, J.W. & Kaelin, W.G. Jr 2002. Biochemical purification and pharmacological inhibition of a mammalian prolyl hydroxylase acting on hypoxia-inducible factor. Proc Natl Acad Sci USA 99, 13459-13464.
79. 2-regulated prolyl hydroxylation. Science 292, 468-472.
80. Jamadarkhana, P., Chaudhary, A., Chhipa, L., Dubey, A., Mohanan, A., Gupta, R. & Deshpande, S. 2012. Treatment with a novel hypoxia-inducible factor hydroxylase inhibitor (TRC160334) ameliorates ischemic acute kidney injury. Am J Nephrol 36, 208-218.
81. Jokilehto, T. & Jaakkola, P.M. 2010. The role of HIF prolyl hydroxylases in tumour growth. J Cell Mol Med 14, 758-770.
82. 2 sensing and cancer. Nat Rev Cancer 8, 865-873.
83. Kaelin, W.G. Jr 2011. Cancer and altered metabolism: potential importance of hypoxia-inducible factor and 2-oxoglutarate-dependent dioxygenases. Cold Spring Harb Symp Quant Biol 76, 335-345.
84. Kaelin, W.G. Jr & Ratcliffe, P.J. 2008. Oxygen sensing by metazoans: the central role of the HIF hydroxylase pathway. Mol Cell 30, 393-402.
85. Kapitsinou, P.P., Jaffe, J., Michael, M., Swan, C.E., Duffy, K.J., Erickson-Miller, C.L. & Haase, V.H. 2012. Preischemic targeting of HIF prolyl hydroxylation inhibits fibrosis associated with acute kidney injury. Am J Physiol Renal Physiol 302, F1172-F1179.
86. Keith, B. & Simon, M.C. 2007. Hypoxia-inducible factors, stem cells, and cancer. Cell 129, 465-472.
87. Keith, B., Johnson, R.S. & Simon, M.C. 2011. HIF1α and HIF2α: sibling rivalry in hypoxic tumour growth and progression. Nat Rev Cancer 12, 9-22.
88. Kiss, J., Mollenhauer, M., Walmsley, S.R., Kirchberg, J., Radhakrishnan, P., Niemietz, T., Dudda, J., Steinert, G., Whyte, M.K., Carmeliet, P., Mazzone, M., Weitz, J. & Schneider, M. 2012. Loss of the oxygen sensor PHD3 enhances the innate immune response to abdominal sepsis. J Immunol 189, 1955-1965.
89. Klotzsche-von Ameln, A., Muschter, A., Heimesaat, M.M., Breier, G. & Wielockx, B. 2012. HIF prolyl hydroxylase-2 inhibition diminishes tumor growth through matrix metalloproteinase-induced TGFβ activation. Cancer Biol Ther 13, 216-223.
90. Knowles, H.J., Raval, R.R., Harris, A.L. & Ratcliffe, P.J. 2003. Effect of ascorbate on the activity of hypoxia-inducible factor in cancer cells. Cancer Res 63, 1764-1768.
91. Köditz, J., Nesper, J., Stiehl, D.P., Camenisch, G., Franke, C., Myllyharju, J., Wenger, R.H. & Katschinski, D.M. 2007. Oxygen-dependent ATF-4 stability is mediated by the PHD3 oxygen sensor. Blood 110, 3610-3617.
92. Koivunen, P., Hirsilä, M., Kivirikko, K.I. & Myllyharju, J. 2006. The length of peptide substrates has a marked effect on hydroxylation by the hypoxia-inducible factor prolyl 4-hydroxylases. J Biol Chem 281, 28712-28720.
93. Koivunen, P., Hirsilä, M., Remes, A.M., Hassinen, I.E., Kivirikko, K.I. & Myllyharju, J. 2007a. Inhibition of hypoxia-inducible factor (HIF) hydroxylases by citric acid cycle intermediates. Possible links between cell metabolism and stabilization of HIF. J Biol Chem 282, 4524-4532.
94. Koivunen, P., Tiainen, P., Hyvärinen, J., Williams, K.E., Sormunen, R., Klaus, S.J., Kivirikko, K.I. & Myllyharju, J. 2007b. An endoplasmic reticulum transmembrane prolyl 4-hydroxylase is induced by hypoxia and acts on hypoxia-inducible factor α. J Biol Chem 282, 30544-30552.
95. Koivunen, P., Lee, S., Duncan, C.G., Lopez, G., Lu, G., Ramkissoon, S., Losman, J.A., Joensuu, P., Bergmann, U., Gross, S. et al. 2012. Transformation by the (R)-enantiomer of 2-hydroxyglutarate linked to EGLN activation. Nature 483, 484-488.
96. Koski, M.K., Hieta, R., Böllner, C., Kivirikko, K.I., Myllyharju, J. & Wierenga, R.K. 2007. The active site of an algal prolyl 4-hydroxylase has a large structural plasticity. J Biol Chem 282, 37112-37123.
97. Kunze, R., Zhou, W., Veltkamp, R., Wielockx, B., Breier, G. & Marti, H.H. 2012. Neuron-specific prolyl-4-hydroxylase domain 2 knockout reduces brain injury after transient cerebral ischemia. Stroke 43, 2748-2756.
98. Kuznetsova, A.V., Meller, J., Schnell, P.O., Nash, J.A., Ignacak, M.L., Sanchez, Y., Conaway, J.W., Conaway, R.C. & Czyzyk-Krzeska, M.F. 2003. von Hippel-Lindau protein binds hyperphosphorylated large subunit of RNA polymerase II through a proline hydroxylation motif and targets it for ubiquitination. Proc Natl Acad Sci USA 100, 2706-2711.
99. Ladroue, C., Carcenac, R., Leporrier, M., Gad, S., Le Hello, C., Galateau-Salle, F., Feunteun, J., Pouysségur, J., Richard, S. & Gardie, B. 2008. PHD2 mutation and congenital erythrocytosis with paraganglioma. N Engl J Med 359, 2685-2692.
100. Ladroue, C., Hoogewijs, D., Gad, S., Carcenac, R., Storti, F., Barrois, M., Gimenez-Roqueplo, A.P., Leporrier, M., Casadevall, N., Hermine, O. et al. 2012. Distinct deregulation of the hypoxia inducible factor by PHD2 mutants identified in germline DNA of patients with polycythemia. Haematologica 97, 9-14.
101. Laitala, A., Aro, E., Walkinshaw, G., Mäki, J.M., Rossi, M., Heikkilä, M., Savolainen, E.-R., Arend, M., Kivirikko, K.I., Koivunen, P. & Myllyharju, J. 2012. Transmembrane prolyl 4-hydroxylase is a fourth prolyl 4-hydroxylase regulating EPO production and erythropoiesis. Blood 120, 3336-3344.
102. Lando, D., Peet, D.J., Whelan, D.A., Gorman, J.J. & Whitelaw, M.L. 2002a. Asparagine hydroxylation of the HIF transactivation domain a hypoxic switch. Science 295, 858-861.
103. Lando, D., Peet, D.J., Gorman, J.J., Whelan, D.A., Whitelaw, M.L. & Bruick, R.K. 2002b. FIH-1 is an asparaginyl hydroxylase enzyme that regulates the transcriptional activity of hypoxia-inducible factor. Genes Dev 16, 1466-1471.
104. Langsetmo, I., Jacob, C., Ho, W.-B., Stephenson, R., Sirenko, O., Sidhu, P., Flippin, L., Seeley, T., Klaus, S., Lin, A. & Liu, D. 2006. Inhibition of HIF prolyl hydroxylases with FG-4539 is neuroprotective in a mouse model of permanent focal ischemia. Stroke 37, 731.
105. Lee, F.S. & Percy, M.J. 2011. The HIF pathway and erythrocytosis. Annu Rev Pathol 6, 165-192.
106. Lee, S., Nakamura, E., Yang, H., Wei, W., Linggi, M.S., Sajan, M.P., Farese, R.V., Freeman, R.S., Carter, B.D., Kaelin, W.G. Jr & Schlisio, S. 2005. Neuronal apoptosis linked to EglN3 prolyl hydroxylase and familial pheochromocytoma genes: developmental culling and cancer. Cancer Cell 8, 155-167.
107. Lee, D.W., Rajagopalan, S., Siddiq, A., Gwiazda, R., Yang, L., Beal, M.F., Ratan, R.R. & Andersen, J.K. 2009. Inhibition of prolyl hydroxylase protects against 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine-induced neurotoxicity: model for the potential involvement of the hypoxia-inducible factor pathway in Parkinson disease. J Biol Chem 284, 29065-29076.
108. Leite de Oliveira, R., Deschoemaeker, S., Henze, A.T., Debackere, K., Finisguerra, V., Takeda, Y., Roncal, C., Dettori, D., Tack, E., Jönsson, Y. et al. 2012. Gene-targeting of Phd2 improves tumor response to chemotherapy and prevents side-toxicity. Cancer Cell 22, 263-277.
109. Li, N., Yi, F., Sundy, C.M., Chen, L., Hilliker, M.L., Donley, D.K., Muldoon, D.B. & Li, P.L. 2007. Expression and actions of HIF prolyl-4-hydroxylase in the rat kidneys. Am J Physiol Renal Physiol 292, F207-F216.
110. Lieb, M.E., Menzies, K., Moschella, M.C., Ni, R. & Taubman, M.B. 2002. Mammalian EGLN genes have distinct patterns of mRNA expression and regulation. Biochem Cell Biol 80, 421-426.
111. Linden, T., Katschinski, D.M., Eckhardt, K., Scheid, A., Pagel, H. & Wenger, R.H. 2003. The antimycotic ciclopirox olamine induces HIF-1α stability, VEGF expression, and angiogenesis. FASEB J 17, 761-763.
112. Loenarz, C. & Schofield, C.J. 2011. Physiological and biochemical aspects of hydroxylations and demethylations catalyzed by human 2-oxoglutarate oxygenases. Trends Biochem Sci 36, 7-18.
113. Loenarz, C., Coleman, M.L., Boleininger, A., Schierwater, B., Holland, P.W., Ratcliffe, P.J. & Schofield, C.J. 2011. The hypoxia-inducible transcription pathway regulates oxygen sensing in the simplest animal, Trichoplax adhaerens. EMBO Rep 12, 63-70.
114. Loinard, C., Ginouvès, A., Vilar, J., Cochain, C., Zouggari, Y., Recalde, A., Duriez, M., Lévy, B.I., Pouysségur, J., Berra, E. & Silvestre, J.S. 2009. Inhibition of prolyl hydroxylase domain proteins promotes therapeutic revascularization. Circulation 120, 50-59.
115. Lu, H., Dalgard, C.L., Mohyeldin, A., McFate, T., Tait, A.S. & Verma, A. 2005. Reversible inactivation of HIF-1 prolyl hydroxylases allows cell metabolism to control basal HIF-1. J Biol Chem 280, 41928-41939.
116. Macdougall, I.C. 2012. New anemia therapies: translating novel strategies from bench to bedside. Am J Kidney Dis 59, 444-451.
117. Macdougall, I.C. & Eckardt, K.-U. 2006. Novel strategies for stimulating erythropoiesis and potential new treatments for anaemia. Lancet 368, 947-953.
118. Majmundar, A.J., Wong, W.J. & Simon, M.C. 2010. Hypoxia-inducible factors and the response to hypoxic stress. Mol Cell 40, 294-309.
119. Marxsen, J.H., Stengel, P., Doege, K., Heikkinen, P., Jokilehto, T., Wagner, T., Jelkmann, W., Jaakkola, P. & Metzen, E. 2004. Hypoxia-inducible factor-1 (HIF-1) promotes its degradation by induction of HIF-α-prolyl-4-hydroxylases. Biochem J 381, 761-767.
120. Mazzone, M., Dettori, D., Leite de Oliveira, R., Loges, S., Schmidt, T., Jonckx, B., Tian, Y.-M., Lanahan, A.A., Pollard, P., Ruiz de Almodovar, C. et al. 2009. Heterozygous deficiency of PHD2 restores tumor oxygenation and inhibits metastasis via endothelial normalization. Cell 136, 839-851.
121. McDonough, M.A., Li, V., Flashman, E., Chowdhury, R., Mohr, C., Liénard, B.M., Zondlo, J., Oldham, N.J., Clifton, I.J., Lewis, J. et al. 2006. Cellular oxygen sensing: crystal structure of hypoxia-inducible factor prolyl hydroxylase (PHD2). Proc Natl Acad Sci USA 103, 9814-9819.
122. McDonough, M.A., Loenarz, C., Chowdhury, R., Clifton, I.J. & Schofield, C.J. 2010. Structural studies on human 2-oxoglutarate dependent oxygenases. Curr Opin Struct Biol 20, 659-672.
123. McMullin, M.F. 2010. HIF pathway mutations and erythrocytosis. Expert Rev Hematol 3, 93-101.
124. McNeill, L.A., Flashman, E., Buck, M.R.G., Hewitson, K.S., Clifton, I.J., Jeschke, G., Glaridge, T.D., Ehrismann, D., Oldham, N.J. & Schofield, C.J. 2005. Hypoxia-inducible factor prolyl hydroxylase 2 has a high affinity for ferrous iron and 2-oxoglutarate. Mol BioSyst 1, 321-324.
125. Metzen, E., Berchner-Pfannschmidt, U., Stengel, P., Marxsen, J.H., Stolze, I., Klinger, M., Huang, W.Q., Wotzlaw, C., Hellwig-Bürgel, T., Jelkmann, W., Acker, H. & Fandrey, J. 2003. Intracellular localisation of human HIF-1α hydroxylases: implications for oxygen sensing. J Cell Sci 116, 1319-1326.
126. Metzen, E., Stiehl, D.P., Doege, K., Marxsen, J.H., Hellwig-Bürgel, T. & Jelkmann, W. 2005. Regulation of the prolyl hydroxylase domain protein 2 (phd2/egln-1) gene: identification of a functional hypoxia-responsive element. Biochem J 387, 711-717.
127. Mikhaylova, O., Ignacak, M.L., Barankiewicz, T.J., Harbaugh, S.V., Yi, Y., Maxwell, P.H., Schneider, M., Van Geyte, K., Carmeliet, P., Revelo, M.P., Wyder, M., Greis, K.D., Meller, J. & Czyzyk-Krzeska, M.F. 2008. The von Hippel-Lindau tumor suppressor protein and Egl-9-type proline hydroxylases regulate the large subunit of RNA polymerase II in response to oxidative stress. Mol Cell Biol 28, 2701-2717.
128. Min, J.-H., Yang, H., Ivan, M., Gertler, F., Kaelin, W.G. Jr & Pavletich, N.P. 2002. Structure of an HIF-1α-pVHL complex: hydroxyproline recognition and signaling. Science 296, 1886-1889.
129. Minamishima, Y.A. & Kaelin, W.G. Jr 2010. Reactivation of hepatic EPO synthesis in mice after PHD loss. Science 329, 407.
130. Minamishima, Y.A., Moslehi, J., Bardeesy, N., Cullen, D., Bronson, R.T. & Kaelin, W.G. Jr 2008. Somatic inactivation of the PHD2 prolyl hydroxylase causes polycythemia and congestive heart failure. Blood 111, 3236-3244.
131. Minamishima, Y.A., Moslehi, J., Padera, R.F., Bronson, R.T., Liao, R. & Kaelin, W.G. Jr 2009. A feedback loop involving the Phd3 prolyl hydroxylase tunes the mammalian hypoxic response in vivo. Mol Cell Biol 29, 5729-5741.
132. Mollenhauer, M., Kiss, J., Dudda, J., Kirchberg, J., Rahbari, N., Radhakrishnan, P., Niemietz, T., Rausch, V., Weitz, J. & Schneider, M. 2012. Deficiency of the oxygen sensor PHD1 augments liver regeneration after partial hepatectomy. Langenbecks Arch Surg 397, 1313-1322.
133. Moslehi, J., Minamishima, Y.A., Shi, J., Neuberg, D., Charytan, D.M., Padera, R.F., Signoretti, S., Liao, R. & Kaelin, W.G. Jr 2009. Loss of hypoxia-inducible factor prolyl hydroxylase activity in cardiomyocytes phenocopies ischemic cardiomyopathy. Circulation 122, 1004-1016.
134. Murray, J.K., Balan, C., Allgeier, A.M., Kasparian, A., Viswanadhan, V., Wilde, C., Allen, J.R., Yoder, S.C., Biddlecome, G., Hungate, R.W. & Miranda, L.P. 2010. Dipeptidyl-quinolone derivatives inhibit hypoxia inducible factor-1α prolyl hydroxylases-1, -2, and -3 with altered selectivity. J Comb Chem 12, 676-686.
135. Myllyharju, J. 2008. Prolyl 4-hydroxylases, key enzymes in the synthesis of collagens and regulation of the response to hypoxia, and their roles as treatment targets. Ann Med 40, 402-417.
136. Myllyharju, J. 2009. HIF prolyl 4-hydroxylases and their potential as drug targets. Curr Pharm Des 15, 3878-3885.
137. Myllyharju, J. & Kivirikko, K.I. 1997. Characterization of the iron- and 2-oxoglutarate-binding sites of human prolyl 4-hydroxylase. EMBO J 16, 1173-1180.
138. Myllyharju, J. & Kivirikko, K.I. 2004. Collagens, modifying enzymes and their mutations in humans, flies and worms. Trends Genet 20, 33-43.
139. Myllyharju, J. & Schipani, E. 2010. Extracellular matrix genes as hypoxia-inducible targets. Cell Tissue Res 339, 19-29.
140. Nagel, S., Talbot, N.P., Mecinović, J., Smith, T.G., Buchan, A.M. & Schofield, C.J. 2010. Therapeutic manipulation of the HIF hydroxylases. Antioxid Redox Signal 12, 481-501.
141. Nagel, S., Papadakis, M., Chen, R., Hoyte, L.C., Brooks, K.J., Gallichan, D., Sibson, N.R., Pugh, C. & Buchan, A.M. 2011. Neuroprotection by dimethyloxalylglycine following permanent and transient focal cerebral ischemia in rats. J Cereb Blood Flow Metab 31, 132-143.
142. Nangaku, M., Izuhara, Y., Takizawa, S., Yamashita, T., Fujii-Kuriyama, Y., Ohneda, O., Yamamoto, M., van Ypersele de Strihou, C., Hirayama, N. & Miyata, T. 2007. A novel class of prolyl hydroxylase inhibitors induces angiogenesis and exerts organ protection against ischemia. Arterioscler Thromb Vasc Biol 27, 2548-2554.
143. Nizet, V. & Johnson, R.S. 2009. Interdependence of hypoxic and innate immune responses. Nat Rev Immunol 9, 609-617.
144. Nytko, K.J., Maeda, N., Schläfli, P., Spielmann, P., Wenger, R.H. & Stiehl, D.P. 2011. Vitamin C is dispensable for oxygen sensing in vivo. Blood 117, 5485-5493.
145. Ockaili, R., Natarajan, R., Salloum, F., Fisher, B.J., Jones, D., Fowler, A.A. III & Kukreja, R.C. 2005. HIF-1 activation attenuates postischemic myocardial injury: role for heme oxygenase-1 in modulating microvascular chemokine generation. Am J Physiol Heart Circ Physiol 289, H542-H548.
146. Oehme, F., Ellinghaus, P., Kolkhof, P., Smith, T.J., Ramakrishnan, S., Hütter, J., Schramm, M. & Flamme, I. 2002. Overexpression of PH-4, a novel putative proline 4-hydroxylase, modulates activity of hypoxia-inducible transcription factors. Biochem Biophys Res Commun 296, 343-349.
147. Ogle, M.E., Gu, X., Espinera, A.R. & Wei, L. 2012. Inhibition of prolyl hydroxylases by dimethyloxaloylglycine after stroke reduces ischemic brain injury and requires hypoxia inducible factor-1α. Neurobiol Dis 45, 733-742.
148. Okumura, C.Y., Hollands, A., Tran, D.N., Olson, J., Dahesh, S., von Köckritz-Blickwede, M., Thienphrapa, W., Corle, C., Jeung, S.N., Kotsakis, A., Shalwitz, R.A., Johnson, R.S. & Nizet, V. 2012. A new pharmacological agent (AKB-4924) stabilizes hypoxia inducible factor-1 (HIF-1) and increases skin innate defenses against bacterial infection. J Mol Med 90, 1079-1089.
149. Oliver, K.M., Taylor, C.T. & Cummins, E.P. 2009. Hypoxia. Regulation of NFκB signalling during inflammation: the role of hydroxylases. Arthritis Res Ther 11, 215.
150. Ozer, A. & Bruick, R.K. 2007. Non-heme dioxygenases: cellular sensors and regulators jelly rolled into one? Nat Chem Biol 3, 144-153.
151. Pajusola, K., Künnapuu, J., Vuorikoski, S., Soronen, J., André, H., Pereira, T., Korpisalo, P., Ylä-Herttuala, S., Poellinger, L. & Alitalo, K. 2005. Stabilized HIF-1α is superior to VEGF for angiogenesis in skeletal muscle via adeno-associated virus gene transfer. FASEB J 19, 1365-1367.
152. Pappalardi, M.B., Martin, J.D., Jiang, Y., Burns, M.C., Zhao, H., Ho, T., Sweitzer, S., Lor, L., Schwartz, B., Duffy, K., Gontarek, R., Tummino, P.J., Copeland, R.A. & Luo, L. 2008. Biochemical characterization of human prolyl hydroxylase domain protein 2 variants associated with erythrocytosis. Biochemistry 47, 11165-11167.
153. Pasanen, A., Heikkilä, M., Rautavuoma, K., Hirsilä, M., Kivirikko, K.I. & Myllyharju, J. 2010. Hypoxia-inducible factor (HIF)-3α is subject to extensive alternative splicing in human tissues and cancer cells and is regulated by HIF-1 but not HIF-2. Int J Biochem Cell Biol 42, 1189-1200.
154. Patel, S.A. & Simon, M.C. 2008. Biology of hypoxia-inducible factor-2α in development and disease. Cell Death Differ 15, 628-634.
155. Percy, M.J., Zhao, Q., Flores, A., Harrison, C., Lappin, T.R.J., Maxwell, P.H., McMullin, M.F. & Lee, F.S. 2006. A family with erythrocytosis establishes a role for prolyl hydroxylase domain protein 2 in oxygen homeostasis. Proc Natl Acad Sci USA 103, 654-659.
156. Percy, M.J., Furlow, P.W., Beer, P.A., Lappin, T.R., McMullin, M.F. & Lee, F.S. 2007. A novel erythrocytosis-associated PHD2 mutation suggests the location of a HIF binding groove. Blood 11, 2193-2196.
157. del Peso, L., Castellanos, M.C., Temes, E., Martín-Puig, S., Cuevas, Y., Olmos, G. & Landazuri, M.O. 2003. The von Hippel Lindau/hypoxia-inducible factor (HIF) pathway regulates the transcription of the HIF-proline hydroxylase genes in response to low oxygen. J Biol Chem 278, 48690-48695.
158. Philipp, S., Jürgensen, J.S., Fielitz, J., Bernhardt, W.M., Weidemann, A., Schiche, A., Pilz, B., Dietz, R., Regitz-Zagrosek, V., Eckardt, K.U. & Willenbrock, R. 2006. Stabilization of hypoxia inducible factor rather than modulation of collagen metabolism improves cardiac function after acute myocardial infarction in rats. Eur J Heart Fail 8, 347-354.
159. Pollard, P.J., Brière, J.J., Alam, N.A., Barwell, J., Barclay, E., Wortham, N.C., Hunt, T., Mitchell, M., Olpin, S., Moat, S.J. et al. 2005. Accumulation of Krebs cycle intermediates and over-expression of HIF1α in tumours which result from germline FH and SDH mutations. Hum Mol Genet 14, 2231-2239.
160. Pollard, P.J., Spencer-Dene, B., Shukla, D., Howarth, K., Nye, E., El-Bahrawy, M., Deheragoda, M., Joannou, M., McDonald, S., Martin, A. et al. 2007. Targeted inactivation of fh1 causes proliferative renal cyst development and activation of the hypoxia pathway. Cancer Cell 11, 311-319.
161. Pugh, C.W. & Ratcliffe, P.J. 2003. Regulation of angiogenesis by hypoxia: role of the HIF system. Nat Med 9, 677-684.
162. Querbes, W., Bogorad, R.L., Moslehi, J., Wong, J., Chan, A.Y., Bulgakova, E., Kuchimanchi, S., Akinc, A., Fitzgerald, K., Koteliansky, V. & Kaelin, W.G. Jr 2012. Treatment of erythropoietin deficiency in mice with systemically administered siRNA. Blood 120, 1916-1922.
163. Raimundo, N., Baysal, B.E. & Shadel, G.S. 2011. Revisiting the TCA cycle: signaling to tumor formation. Trends Mol Med 17, 641-649.
164. Rankin, E.B. & Giaccia, A.J. 2008. The role of hypoxia-inducible factors in tumorigenesis. Cell Death Differ 15, 678-685.
165. Rey, S. & Semenza, G.L. 2010. Hypoxia-inducible factor-1-dependent mechanisms of vascularization and vascular remodelling. Cardiovasc Res 86, 236-242.
166. Rey, S., Lee, K., Wang, C.J., Gupta, K., Chen, S., McMillan, A., Bhise, N., Levchenko, A. & Semenza, G.L. 2009. Synergistic effect of HIF-1α gene therapy and HIF-1-activated bone marrow-derived angiogenic cells in a mouse model of limb ischemia. Proc Natl Acad Sci USA 106, 20399-20404.
167. Ricard-Blum, S. 2011. The collagen family. Cold Spring Harb Perspect Biol 3, a004978.
168. Robinson, A., Keely, S., Karhausen, J., Gerich, M.E., Furuta, G.T. & Colgan, S.P. 2008. Mucosal protection by hypoxia-inducible factor prolyl hydroxylase inhibition. Gastroenterology 134, 145-155.
169. Roda, J.M., Wang, Y., Sumner, L.A., Phillips, G.S., Marsh, C.B. & Eubank, T.D. 2012. Stabilization of HIF-2α induces sVEGFR-1 production from tumor-associated macrophages and decreases tumor growth in a murine melanoma model. J Immunol 189, 3168-3177.
170. Rohrbach, S., Simm, A., Pregla, R., Franke, C. & Katschinski, D.M. 2005. Age-dependent increase of prolyl-4-hydroxylase domain (PHD) 3 expression in human and mouse heart. Biogerontology 6, 165-171.
171. Rohrbach, S., Teichert, S., Niemann, B., Franke, C. & Katschinski, D.M. 2008. Caloric restriction counteracts age-dependent changes in prolyl-4-hydroxylase domain (PHD) 3 expression. Biogerontology 9, 169-176.
172. Rose, N.R., McDonough, M.A., King, O.N., Kawamura, A. & Schofield, C.J. 2011. Inhibition of 2-oxoglutarate dependent oxygenases. Chem Soc Rev 40, 4364-4397.
173. Rosenberger, C., Rosen, S., Shina, A., Frei, U., Eckardt, K.U., Flippin, L.A., Arend, M., Klaus, S.J. & Heyman, S.N. 2008. Activation of hypoxia-inducible factors ameliorates hypoxic distal tubular injury in the isolated perfused rat kidney. Nephrol Dial Transplant 23, 3472-3478.
174. Sarkar, K., Fox-Talbot, K., Steenbergen, C., Bosch-Marcé, M. & Semenza, G.L. 2009. Adenoviral transfer of HIF-1α enhances vascular responses to critical limb ischemia in diabetic mice. Proc Natl Acad Sci USA 106, 18769-18774.
175. Sarkar, K., Cai, Z., Gupta, R., Parajuli, N., Fox-Talbot, K., Darshan, M.S., Gonzalez, F.J. & Semenza, G.L. 2012. Hypoxia-inducible factor 1 transcriptional activity in endothelial cells is required for acute phase cardioprotection induced by ischemic preconditioning. Proc Natl Acad Sci USA 109, 10504-10509.
176. Schlisio, S., Kenchappa, R.S., Vredeveld, L.C., George, R.E., Stewart, R., Greulich, H., Shahriari, K., Nguyen, N.V., Pigny, P., Dahia, P.L. et al. 2008. The kinesin KIF1Bβ acts downstream from EglN3 to induce apoptosis and is a potential 1p36 tumor suppressor. Genes Dev 22, 884-893.
177. Schneider, M., Van Geyte, K., Fraisl, P., Kiss, J., Aragonés, J., Mazzone, M., Mairbäurl, H., De Bock, K., Jeoung, N.H., Mollenhauer, M. et al. 2010. Loss or silencing of the PHD1 prolyl hydroxylase protects livers of mice against ischemia/reperfusion injury. Gastroenterology 138, 1143-1154.
178. Schödel, J., Klanke, B., Weidemann, A., Buchholz, B., Bernhardt, W., Bertog, M., Amann, K., Korbmacher, C., Wiesener, M., Warnecke, C., Kurtz, A., Eckardt, K.U. & Willam, C. 2009. HIF-prolyl hydroxylases in the rat kidney: physiologic expression patterns and regulation in acute kidney injury. Am J Pathol 174, 1663-1674.
179. Schofield, C.J. & Ratcliffe, P.J. 2004. Oxygen sensing by HIF hydroxylases. Nat Rev Mol Cell Biol 5, 343-354.
180. Sears, J.E., Hoppe, G., Ebrahem, Q. & Anand-Apte, B. 2008. Prolyl hydroxylase inhibition during hyperoxia prevents oxygen-induced retinopathy. Proc Natl Acad Sci USA 105, 19898-19903.
181. Sekirnik, R., Rose, N.R., Mecinović, J. & Schofield, C.J. 2010. 2-Oxoglutarate oxygenases are inhibited by a range of transition metals. Metallomics 2, 397-399.
182. Selak, M.A., Armour, S.M., MacKenzie, E.D., Boulahbel, H., Watson, D.G., Mansfield, K.D., Pan, Y., Simon, M.C., Thompson, C.B. & Gottlieb, E. 2005. Succinate links TCA cycle dysfunction to oncogenesis by inhibiting HIF-α prolyl hydroxylase. Cancer Cell 7, 77-85.
183. Semenza, G.L. 2011. Oxygen sensing, homeostasis, and disease. N Engl J Med 365, 537-547.
184. Semenza, G.L. 2012a. Hypoxia-inducible factors in physiology and medicine. Cell 148, 399-408.
185. Semenza, G.L. 2012b. Hypoxia-inducible factors: mediators of cancer progression and targets for cancer therapy. Trends Pharmacol Sci 33, 207-214.
186. Siddiq, A., Ayoub, I.A., Chavez, J.C., Aminova, L., Shah, S., LaManna, J.C., Patton, S.M., Connor, J.R., Cherny, R.A., Volitakis, I., Bush, A.I., Langsetmo, I., Seeley, T., Günzler, V. & Ratan, R.R. 2005. Hypoxia-inducible factor prolyl 4-hydroxylase inhibition. A target for neuroprotection in the central nervous system. J Biol Chem 280, 41732-41743.
187. Sridharan, V., Guichard, J., Bailey, R.M., Kasiganesan, H., Beeson, C. & Wright, G.L. 2007. The prolyl hydroxylase oxygen-sensing pathway is cytoprotective and allows maintenance of mitochondrial membrane potential during metabolic inhibition. Am J Physiol Cell Physiol 292, C719-C728.
188. Stiehl, D.P., Wirthner, R., Köditz, J., Spielmann, P., Camenisch, G. & Wenger, R.H. 2006. Increased prolyl 4-hydroxylase domain proteins compensate for decreased oxygen levels. Evidence for an autoregulatory oxygen-sensing system. J Biol Chem 281, 23482-23491.
189. Su, Y., Loos, M., Giese, N., Hines, O.J., Diebold, I., Görlach, A., Metzen, E., Pastorekova, S., Friess, H. & Büchler, P. 2010. PHD3 regulates differentiation, tumour growth and angiogenesis in pancreatic cancer. Br J Cancer 103, 1571-1579.
190. Su, Y., Loos, M., Giese, N., Metzen, E., Büchler, M.W., Friess, H., Kornberg, A. & Büchler, P. 2012. Prolyl hydroxylase-2 (PHD2) exerts tumor-suppressive activity in pancreatic cancer. Cancer 118, 960-972.
191. Takaku, M., Tomita, S., Kurobe, H., Kihira, Y., Morimoto, A., Higashida, M., Ikeda, Y., Ushiyama, A., Hashimoto, I., Nakanishi, H. & Tamaki, T. 2012. Systemic preconditioning by a prolyl hydroxylase inhibitor promotes prevention of skin flap necrosis via HIF-1-induced bone marrow-derived cells. PLoS ONE 7, e42964.
192. Takeda, K., Ho, V.C., Takeda, H., Duan, L.-J., Nagy, A. & Fong, G.-H. 2006. Placental but not heart defects are associated with elevated hypoxia-inducible factor α levels in mice lacking prolyl hydroxylase domain protein 2. Mol Cell Biol 26, 8336-8346.
193. Takeda, K., Cowan, A. & Fong, G.-H. 2007. Essential role for prolyl hydroxylase domain protein 2 in oxygen homeostasis of the adult vascular system. Circulation 116, 774-781.
194. Takeda, K., Aguila, H.L., Parikh, N.S., Li, X., Lamothe, K., Duan, L.-J., Takeda, H., Lee, F.S. & Fong, G.-H. 2008. Regulation of adult erythropoiesis by prolyl hydroxylase domain proteins. Blood 111, 3229-3235.
195. Takeda, Y., Costa, S., Delamarre, E., Roncal, C., Leite de Oliveira, R., Squadrito, M.L., Finisguerra, V., Deschoemaeker, S., Bruyère, F., Wenes, M. et al. 2011. Macrophage skewing by Phd2 haplodeficiency prevents ischaemia by inducing arteriogenesis. Nature 479, 122-126.
196. Tambuwala, M.M., Cummins, E.P., Lenihan, C.R., Kiss, J., Stauch, M., Scholz, C.C., Fraisl, P., Lasitschka, F., Mollenhauer, M., Saunders, S.P., Maxwell, P.H., Carmeliet, P., Fallon, P.G., Schneider, M. & Taylor, C.T. 2010. Loss of prolyl hydroxylase-1 protects against colitis through reduced epithelial cell apoptosis and increased barrier function. Gastroenterology 139, 2093-2101.
197. Tanaka, T., Wiesener, M., Bernhardt, W., Eckardt, K.U. & Warnecke, C. 2009. The human HIF (hypoxia-inducible factor)-3α gene is a HIF-1 target gene and may modulate hypoxic gene induction. Biochem J 424, 143-151.
198. Tian, Y.M., Mole, D.R., Ratcliffe, P.J. & Gleadle, J.M. 2006. Characterization of different isoforms of the HIF prolyl hydroxylase PHD1 generated by alternative initiation. Biochem J 397, 179-186.
199. Tian, Y.M., Yeoh, K.K., Lee, M.K., Eriksson, T., Kessler, B.M., Kramer, H.B., Edelmann, M.J., Willam, C., Pugh, C.W., Schofield, C.J. & Ratcliffe, P.J. 2011. Differential sensitivity of hypoxia inducible factor hydroxylation sites to hypoxia and hydroxylase inhibitors. J Biol Chem 286, 13041-13051.
200. To, K.K.W. & Huang, L.E. 2005. Suppression of hypoxia-inducible factor 1α (HIF-1α) transcriptional activity by the HIF prolyl hydroxylase EGLN1. J Biol Chem 280, 38102-38107.
201. Vachal, P., Miao, S., Pierce, J.M., Guiadeen, D., Colandrea, V.J., Wyvratt, M.J., Salowe, S.P., Sonatore, L.M., Milligan, J.A., Hajdu, R. et al. 2012. 1, 3, 8-Triazaspiro[4.5]decane-2, 4-diones as efficacious pan-inhibitors of hypoxia-inducible factor prolyl hydroxylase 1-3 (HIF PHD1-3) for the treatment of anemia. J Med Chem 55, 2945-2959.
202. Vincent, K.A., Jiang, C., Boltje, I. & Kelly, R.A. 2007. Gene therapy progress and prospects: therapeutic angiogenesis for ischemic cardiovascular disease. Gene Ther 14, 781-789.
203. Vogel, J. & Gassmann, M. 2011. Erythropoietic and non-erythropoietic functions of erythropoietin in mouse models. J Physiol 589, 1259-1264.
204. Vuorio, T., Jauhiainen, S. & Ylä-Herttuala, S. 2012. Pro- and anti-angiogenic therapy and atherosclerosis with special emphasis on vascular endothelial growth factors. Expert Opin Biol Ther 12, 79-92.
205. Walmsley, S.R., Chilvers, E.R., Thompson, A.A., Vaughan, K., Marriott, H.M., Parker, L.C., Shaw, G., Parmar, S., Schneider, M., Sabroe, I. et al. 2011. Prolyl hydroxylase 3 (PHD3) is essential for hypoxic regulation of neutrophilic inflammation in humans and mice. J Clin Invest 121, 1053-1063.
206. Wang, J., Chen, G., Muckenthaler, M., Galy, B., Hentze, M.W. & Pantopoulos, K. 2004. Iron-mediated degradation of IRP2, an unexpected pathway involving a 2-oxoglutarate-dependent oxygenase activity. Mol Cell Biol 24, 954-965.
207. Wang, Z., Schley, G., Türkoglu, G., Burzlaff, N., Amann, K.U., Willam, C., Eckardt, K.U. & Bernhardt, W.M. 2012. The protective effect of prolyl-hydroxylase inhibition against renal ischaemia requires application prior to ischaemia but is superior to EPO treatment. Nephrol Dial Transplant 27, 929-936.
208. Ward, J.B., Lawler, K., Amu, S., Taylor, C.T., Fallon, P.G. & Keely, S.J. 2011. Hydroxylase inhibition attenuates colonic epithelial secretory function and ameliorates experimental diarrhea. FASEB J 25, 535-543.
209. Warnecke, C., Griethe, W., Weidemann, A., Jürgensen, J.S., Willam, C., Bachmann, S., Ivashchenko, Y., Wagner, I., Frei, U., Wiesener, M. & Eckardt, K.U. 2003. Activation of the hypoxia-inducible factor-pathway and stimulation of angiogenesis by application of prolyl hydroxylase inhibitors. FASEB J 17, 1186-1188.
210. Willam, C., Maxwell, P.H., Nichols, L., Lygate, C., Tian, Y.M., Bernhardt, W., Wiesener, M., Ratcliffe, P.J., Eckardt, K.U. & Pugh, C.W. 2006. HIF prolyl hydroxylases in the rat; organ distribution and changes in expression following hypoxia and coronary artery ligation. J Mol Cell Cardiol 41, 68-77.
211. Witten, L., Sager, T., Thirstrup, K., Johansen, J.L., Larsen, D.B., Montezinho, L.P. & Mørk, A. 2009. HIF prolyl hydroxylase inhibition augments dopamine release in the rat brain in vivo. J Neurosci Res 87, 1686-1694.
212. Wottawa, M., Köditz, J. & Katschinski, D.M. 2010. Normoxic destabilization of ATF-4 depends on proteasomal degradation. Acta Physiol (Oxf) 198, 457-463.
213. 2-adrenergic receptor hydroxylation by EGLN3 and ubiquitylation by pVHL. Sci Signal 2, ra33.
214. Xie, L., Pi, X., Mishra, A., Fong, G., Peng, J. & Patterson, C. 2012. PHD3-dependent hydroxylation of HCLK2 promotes the DNA damage response. J Clin Invest 122, 2827-2836.
215. Yan, B., Huo, Z., Liu, Y., Lin, X., Li, J., Peng, L., Zhao, H., Zhou, Z.N., Liang, X., Liu, Y. et al. 2011. Prolyl hydroxylase 2: a novel regulator of β2 -adrenoceptor internalization. J Cell Mol Med 15, 2712-2722.
216. Yu, F., White, S.B., Zhao, Q. & Lee, F.S. 2001. HIF-1α is regulated by stimulus sensitive proline hydroxylation. Proc Natl Acad Sci USA 98, 9630-9635.
217. Zhang, Q., Gu, J., Li, L., Liu, J., Luo, B., Cheung, H.W., Boehm, J.S., Ni, M., Geisen, C., Root, D.E. et al. 2009. Control of cyclin D1 and breast tumorigenesis by the EglN2 prolyl hydroxylase. Cancer Cell 16, 413-424.